Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -31.54
- Piotroski Score 2.00
- Grade Buy
- Symbol (SNGX)
- Company Soligenix, Inc.
- Price $3.31
- Changes Percentage (-1.49%)
- Change -$0.05
- Day Low $3.28
- Day High $3.41
- Year High $32.00
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/21/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$9.76
- Trailing P/E Ratio -0.39
- Forward P/E Ratio -0.39
- P/E Growth -0.39
- Net Income $-6,140,730
Income Statement
Quarterly
Annual
Latest News of SNGX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
SNGX Stock Price | Soligenix Inc. Stock Quote (U.S.: Nasdaq) | MarketWatch
Soligenix, Inc. is a biopharmaceutical company specializing in rare disease treatments. It is developing products like SGX301 for cutaneous T-cell lymphoma and vaccines for ricin toxin and infectious ...
By MarketWatch | 4 months ago -
Soligenix, Inc. (SNGX) Stock Price, News, Quote & History - Yahoo Finance
Soligenix, Inc. is a biopharmaceutical company in the US focusing on developing and commercializing products for rare diseases. It operates through two segments: Specialized BioTherapeutics and Public...
By Yahoo! Finance | 4 months ago
